CA3095468A1 - Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders - Google Patents
Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders Download PDFInfo
- Publication number
- CA3095468A1 CA3095468A1 CA3095468A CA3095468A CA3095468A1 CA 3095468 A1 CA3095468 A1 CA 3095468A1 CA 3095468 A CA3095468 A CA 3095468A CA 3095468 A CA3095468 A CA 3095468A CA 3095468 A1 CA3095468 A1 CA 3095468A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- carboxylic acid
- pharmaceutically acceptable
- acceptable salt
- dystrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650004P | 2018-03-29 | 2018-03-29 | |
| US62/650,004 | 2018-03-29 | ||
| PCT/US2019/024726 WO2019191525A1 (en) | 2018-03-29 | 2019-03-29 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3095468A1 true CA3095468A1 (en) | 2019-10-03 |
Family
ID=68056529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095468A Pending CA3095468A1 (en) | 2018-03-29 | 2019-03-29 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190298674A1 (https=) |
| EP (1) | EP3758693A4 (https=) |
| JP (1) | JP2021519753A (https=) |
| KR (1) | KR20210009306A (https=) |
| CN (1) | CN112218628A (https=) |
| AU (1) | AU2019243586A1 (https=) |
| CA (1) | CA3095468A1 (https=) |
| IL (1) | IL277599A (https=) |
| MX (1) | MX2020010302A (https=) |
| WO (1) | WO2019191525A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR202021080A2 (tr) * | 2020-12-21 | 2022-07-21 | Marmara Ueniversitesi | Thi̇el-behnke kornea di̇strofi̇si̇ (tbkd) i̇çi̇n bi̇r yöntem ve söz konusu yöntem i̇le üreti̇len bi̇r yapay doku i̇skelesi̇ |
| EP4482478A4 (en) * | 2022-02-27 | 2026-03-04 | Univ Northwestern | (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS USED AS SELECTIVE ORNITHIN AMINOTRANSFERASE ACTIVATORS |
| KR20250034134A (ko) * | 2022-07-06 | 2025-03-10 | 오비드 테라퓨틱스 인크. | 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용 |
| US20240285565A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| JP2026506097A (ja) * | 2023-02-17 | 2026-02-20 | オービッド・セラピューティクス・インコーポレイテッド | 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用 |
| US20240285563A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| ES2882126T3 (es) * | 2014-11-07 | 2021-12-01 | Univ Northwestern | Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular |
| JP6841821B2 (ja) * | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
| US10632088B2 (en) * | 2016-10-10 | 2020-04-28 | Northwestern University | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria |
| EP4692048A3 (en) * | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
| KR20250167147A (ko) * | 2018-02-08 | 2025-11-28 | 오비드 테라퓨틱스 인크. | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| MX2020012691A (es) * | 2018-05-25 | 2021-02-15 | Univ Northwestern | Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico. |
-
2019
- 2019-03-29 JP JP2020552191A patent/JP2021519753A/ja active Pending
- 2019-03-29 CA CA3095468A patent/CA3095468A1/en active Pending
- 2019-03-29 KR KR1020207031345A patent/KR20210009306A/ko not_active Withdrawn
- 2019-03-29 EP EP19777219.7A patent/EP3758693A4/en not_active Withdrawn
- 2019-03-29 US US16/368,907 patent/US20190298674A1/en not_active Abandoned
- 2019-03-29 AU AU2019243586A patent/AU2019243586A1/en not_active Abandoned
- 2019-03-29 MX MX2020010302A patent/MX2020010302A/es unknown
- 2019-03-29 CN CN201980033569.9A patent/CN112218628A/zh active Pending
- 2019-03-29 WO PCT/US2019/024726 patent/WO2019191525A1/en not_active Ceased
-
2020
- 2020-09-24 IL IL277599A patent/IL277599A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020010302A (es) | 2021-01-08 |
| CN112218628A (zh) | 2021-01-12 |
| JP2021519753A (ja) | 2021-08-12 |
| IL277599A (en) | 2020-11-30 |
| AU2019243586A1 (en) | 2020-10-15 |
| EP3758693A1 (en) | 2021-01-06 |
| US20190298674A1 (en) | 2019-10-03 |
| EP3758693A4 (en) | 2021-06-02 |
| WO2019191525A1 (en) | 2019-10-03 |
| KR20210009306A (ko) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3095468A1 (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| EP3681500B1 (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia | |
| JP5878172B2 (ja) | 炎症性眼疾患の治療／予防用化合物 | |
| JP7664239B2 (ja) | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| CN107569494A (zh) | 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂 | |
| CN103566068B (zh) | 具视网膜保护功能的复方组成物及应用 | |
| CN110114066B (zh) | 含沙丁胺醇的眼科药物 | |
| TW200410699A (en) | Use of ANECORTAVE acetate for the protection of visual acuity in patients with age related macular degeneration | |
| WO2022221315A1 (en) | Methods of treating retinal vasculopathies | |
| JP7615139B2 (ja) | 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤 | |
| Yanoff | Ophthalmic diagnosis & treatment | |
| KR20250002220A (ko) | 안구 약물 전달 삽입물을 투여하여 연령 관련 황반 변성을 예방하는 방법 | |
| Shukla et al. | Macular hole secondary to X-linked retinoschisis | |
| JP2014510115A (ja) | 初期の緑内障における正常な視覚機能を回復するｐａｃａｐ（下垂体アデニル酸シクラーゼ活性化ポリペプチド）に基づく眼科用製剤 | |
| WO2023192691A2 (en) | Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease | |
| CN117295520A (zh) | 使用内皮素受体拮抗剂治疗眼部疾病 | |
| Feng et al. | Bilateral spontaneous aqueous misdirection: it can happen! | |
| Narayanaswamy et al. | Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs | |
| Mautino et al. | Side effects of drugs used in ocular treatment | |
| Martinez et al. | Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2 | |
| Merlak et al. | Cistoidni makularni edem nakon operacije katarakte | |
| Merlak et al. | Cystoid macular edema after cataract surgery | |
| Ijeri et al. | Bevacizumab in choroidal neovascularization secondary to Indian tick typhus: A rare case report | |
| HK40034331B (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250915 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251117 |